Protagonist Therapeutics, Inc (PTGX) · Nov 5, 2026 · Earnings
Beat — Diluted EPS $3.07 vs roughly $2.50 consensus
Protagonist earnings beat published Q3 expectations, extending its cash build after two drug approvals—but the quarter offers limited new commercialization detail.
Protagonist is transitioning from a development-stage biotech into a partnered commercial platform. The company now has two FDA-approved medicines, with ICOTYDE launched in the U.S. and MIMRYLO approved for polycythemia vera. 〔0〕
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| License and collaboration revenue (Financial Highlights) | $274.4M (+5,721%) | $4.7M | ~$238.5M–$267.0M |
| Diluted EPS (Income Statement) | $3.07 | $(0.62) | ~$2.19–$2.66 |
| Operating expenses (Income Statement) | $56.1M (+9.7%) | $51.1M | |
| Cash, equivalents and marketable securities (Balance Sheet) | $834.6M (+29.2% vs. Dec. 2025) | $646.0M |
The quarter was a clear financial beat, not merely a year-over-year rebound. License and collaboration revenue of $274.4 million exceeded the published estimate range of roughly $238.5 million to $267.0 million, while diluted EPS of $3.07 also cleared available estimates.
The result strengthens Protagonist’s funding position for its pipeline. Cash, cash equivalents and marketable securities reached $834.6 million at September 30, 2026, while operating expenses rose only modestly despite the company’s expanding program base. The release says ICOTYDE was launched in the U.S. in March 2026 and that the partnerships are intended to fund wholly owned programs. 〔1〕
The limitation is revenue quality and disclosure, not the headline numbers. The filing reports license and collaboration revenue but does not break out product royalties, launch sales, milestone components, or a recurring commercial run-rate for the quarter. That makes the beat useful evidence of near-term financial capacity, but weaker evidence that the underlying commercial engine is already fully proven.
Bottom line: This is a genuine earnings beat that adds cash and validates the partnered model, but it does not yet materially clarify how much of the revenue engine is recurring commercialization versus collaboration economics.أ
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!